News|Videos|November 13, 2023
Amivantamab + Lazertinib in EGFR-Mutated Advanced NSCLC: Results from MARIPOSA
Expert insight into results from MARIPOSA, a study of frontline amivantamab plus lazertinib in advanced non–small cell lung cancer, and the potential for this regimen’s use in real-world practice.
Advertisement
Episodes in this series
Advertisement
Related to this article
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
3
Proton Therapy Does Not Improve Survival in Advanced HCC Trial
4
CD47-Targeted Evorpacept Shows Durable Responses in HER2+ Gastric Cancer
5